drugset / Trial / NCT05148286

Summary

The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.

Timeline

Start
2022-01-17
Primary completion
2027-09-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albumin Protein / enzyme biologic 200 ml